Macro Finance
Fresenius Taps China’s WuXi to Expand Biosimilar Drug Portfolio
Bloomberg Markets·November 2, 2026·1 min read
Fresenius SE agreed to partner with China's WuXi Biologics to develop biosimilar drug candidates that could reach the market within the next decade, potentially more than doubling Fresenius's current biosimilar portfolio. The collaboration aims to expand Fresenius's presence in the growing biosimilars market, leveraging WuXi's manufacturing capabilities.
Read at Bloomberg MarketsDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.